0001614107-19-000002.txt : 20190912 0001614107-19-000002.hdr.sgml : 20190912 20190912132104 ACCESSION NUMBER: 0001614107-19-000002 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20190912 DATE AS OF CHANGE: 20190912 EFFECTIVENESS DATE: 20190912 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Faraday Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001614107 IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-348677 FILM NUMBER: 191090043 BUSINESS ADDRESS: STREET 1: 1616 EASTLAKE AVENUE E. STREET 2: SUITE 560 CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: 2064528700 MAIL ADDRESS: STREET 1: 1616 EASTLAKE AVENUE E. STREET 2: SUITE 560 CITY: SEATTLE STATE: WA ZIP: 98102 D 1 primary_doc.xml X0708 D LIVE 0001614107 Faraday Pharmaceuticals, Inc. 1616 EASTLAKE AVENUE E. SUITE 560 SEATTLE WA WASHINGTON 98102 2064528700 DELAWARE Scion Pharmaceuticals, Inc. None Corporation true Mark Roth c/o Faraday Pharmaceuticals, Inc. 1616 Eastlake Avenue E., Suite 560 Seattle WA WASHINGTON 98102 Director Promoter Steven Gillis c/o Faraday Pharmaceuticals, Inc. 1616 Eastlake Avenue E., Suite 560 Seattle WA WASHINGTON 98102 Director Stephen Hill c/o Faraday Pharmaceuticals, Inc. 1616 Eastlake Avenue E., Suite 560 Seattle WA WASHINGTON 98102 Executive Officer Director Thomas King c/o Faraday Pharmaceuticals, Inc. 1616 Eastlake Avenue E., Suite 560 Seattle WA WASHINGTON 98102 Director Simon Tulloch c/o Faraday Pharmaceuticals, Inc. 1616 Eastlake Avenue E., Suite 560 Seattle WA WASHINGTON 98102 Executive Officer Brian Blackman c/o Faraday Pharmaceuticals, Inc. 1616 Eastlake Avenue E., Suite 560 Seattle WA WASHINGTON 98102 Executive Officer Lawrence Gozlan c/o Faraday Pharmaceuticals, Inc. 1616 Eastlake Avenue E., Suite 560 Seattle WA WASHINGTON 98102 Director Pharmaceuticals Decline to Disclose 06b false 2019-08-29 false true false 0 30065949 25065950 4999999 false 8 0 0 0 false Faraday Pharmaceuticals, Inc. /s/ Brian Blackman Brian Blackman Chief Financial and Business Officer 2019-09-12